%0 Journal Article %A Sylvie Muhimpundu %A Baqiyyah N. Conway %A Shaneda Warren Andersen %A Loren Lipworth %A Mark D. Steinwandel %A William J. Blot %A Xiao-Ou Shu %A Staci L. Sudenga %T Racial Differences in Liver Cancer Incidence and Risk Factors Among a Low Socioeconomic Population %D 2021 %R 10.1101/2021.04.15.21255568 %J medRxiv %P 2021.04.15.21255568 %X Background Liver cancer incidence in the United States is higher among African Americans compared to Whites. The purpose of this study was to examine differences in risk factors associated with Hepatocellular carcinoma (HCC) among Whites and African Americans from low socioeconomic backgrounds in the Southern Community Cohort Study (SCCS).Methods The SCCS is a prospective cohort study with participants from the southeastern US. HCC incidence rates were calculated. Multivariable Cox regression was used to calculate HCC adjusted hazard ratios (aHR) associated with known baseline HCC risk factors for Whites and African Americans, separately.Results There were 294 incident HCC. The incidence rate ratio for HCCwas higher (IRR=1.4, 95%CI: 1.1-1.9) in African Americans compared to Whites. Whites saw a stronger association between self-reported Hepatitis C Virus (aHR= 19.24, 95%CI: 10.58-35.00) and diabetes (aHR= 3.55, 95%CI: 1.96-6.43) for the development of HCCcompared to African Americans (aHR= 7.73, 95%CI: 5.71-10.47 and aHR = 1.48, 95%CI: 1.06-2.06, respectively) even though the prevalence of these risk factors was similar between races. Smoking (aHR= 2.91, 95%CI: 1.87-4.52) and heavy alcohol consumption (aHR= 1.59, 95%CI: 1.19-2.11) were significantly associated with HCC risk among African Americans only.Conclusions In this large prospective cohort, we observed racial differences in HCC incidence and risk factors associated with HCC among African Americans and Whites.Impact Understanding HCC risk differences can assist prevention strategies that target people at high risk, potentially based on risk factors that differ by race.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Southern Community Cohort Study was supported by the NIH (grant numbers R01 CA092447 and U01 CA202979). Drs. Warren Anderson (R00 CA207848) and Sudenga (K07 CA225404) are supported by the National Cancer Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The institutional review boards at Vanderbilt University Medical center and Meharry Medical College approved the study protocol.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData use approved by the Southern Community Cohort Study. https://www.southerncommunitystudy.org/ %U https://www.medrxiv.org/content/medrxiv/early/2021/04/20/2021.04.15.21255568.full.pdf